The FDA has now cleared 225 AI algorithms for cardiology when cardiovascular imaging tools are included, according to an agency inventory update covered by Cardiovascular Business. That volume has pushed hospital purchasing past the pilot stage and into a portfolio-management problem, forcing health systems to build governance, integration checks, and clinical workflow evidence into every buying decision.
The FDA's total count sits at 1,524 cleared AI algorithms. Radiology leads with 1,163, and cardiology holds second place. The specialty lists 146 algorithms "listed specifically under cardiology," but the number climbs to 225 when imaging tools classified elsewhere are counted. For CIOs and clinical engineering leaders, the gap between those two figures is the first operational headache: a cardiology governance committee that tracks only the "cardiology" label will miss a large slice of cardiovascular AI sold through imaging, monitoring, and procedural platforms.
Where the clearances are landing-and why placement matters more than the algorithm
The June 2026 clearance list spans remote monitoring software such as Boston Scientific's BodyGuardian Remote Monitoring System (BGRMS v3.0), echo measurement and navigation updates including Philips' EchoNavigator R5.0, and image assessment tools across multiple modalities. Cardiovascular Business also flagged use cases covering angiography image improvement, in-lab cath guidance, EP ablation guidance, and automated echocardiography quantification.
These categories look uniform on a spreadsheet but create very different operational burdens. Remote monitoring tools force questions about alert routing, staffing coverage, and whether output lands in the EHR or stays locked inside a vendor portal. Cath lab and imaging guidance tools introduce latency, workstation, and modality integration requirements. Echo quantification changes sonographer workflows and reading protocols-the place where adoption most often succeeds or collapses.
A 2025 review of randomized controlled trials evaluating AI in cardiology, available via PubMed Central, shows why implementation stalls: evidence quality and endpoints vary widely across studies. That does not negate value. It means a buyer must define which outcome gets measured locally and what operational change is required to reach it.
New vendors are arriving with clearances and fresh funding
The FDA list is not a static catalogue. On July 6, 2026, Cardiovascular Business reported that Pathway Labs, an AI company founded by cardiologist Pierre Elias, gained FDA clearance and raised $8.5 million. The pairing of a new clearance with new capital signals that more offerings will reach buyers before they have built deep implementation track records.
That shifts the diligence question. For providers, the cost line that escalates quietly is not the software license. It is the integration work, the clinical champions, and the protocol updates needed to turn a cleared algorithm into a durable clinical service. FDA clearance is now table stakes. The differentiator is which vendor can integrate, support, and keep a model current without breaking a clinical process. For teams evaluating how AI for Healthcare fits into existing operations, those integration costs often determine whether a deployment succeeds.
What AliveCor's six-year clearance trail says about update cadence
AliveCor illustrates how long the cardiology AI product cycle can run. Healio Cardiology reported in November 2020 that the company announced 510(k) clearance for next-generation AI algorithms for ECG interpretation on a personal device. Cardiovascular Business' June 2026 clearance roundup listed AliveCor again with "Corvair Monza," showing continued regulatory activity years later.
For hospital IT and clinical leadership, the takeaway is practical. AI that starts in consumer or ambulatory contexts can evolve into adjacent clinical products with refreshed clearances. That evolution can expand capability. It can also create version sprawl if departments buy independently and later try to consolidate.
Why this matters for hospital sourcing and governance this budget cycle
Cardiology's clearance volume is now high enough that health systems can treat it like imaging IT: standardize intake, define technical requirements, and stop approving one-off exceptions. The FDA list provides the market map. The operational work is building a shortlist clinicians will actually use.
For EHR and integration teams, require a dataflow diagram for any cardiology AI tool under review. It must show where inputs come from-modality, device, or ECG system-and where outputs land: EHR, PACS, cath lab system, or vendor portal. If the vendor cannot produce this, the pilot will stall. For service line and nursing leadership, classify each tool by operational burden, especially alert volume and coverage requirements for remote monitoring products. Decide who owns the inbox before the contract is signed. For procurement and legal, add an "update and revalidation" clause. AliveCor's multi-year clearance trail is a concrete reason to ask how model updates are delivered, tested, and communicated, and whether an update triggers retraining or protocol changes. For cardiology chiefs and quality teams, pick one measurable endpoint per deployment and a timeline to judge it. The PubMed review of randomized trials is a reminder that evidence varies, so local measurement plans must be explicit. Teams handling the administrative side of these purchases may also find that AI for Medical Billers creates parallel governance questions around integration and workflow ownership.
Your membership also unlocks:
